Retrophin Inc. (RTRX)

28.81
NASDAQ : Health Technology
Prev Close 27.89
Day Low/High 27.82 / 28.82
52 Wk Low/High 17.52 / 29.77
Avg Volume 290.30K
Exchange NASDAQ
Shares Outstanding 39.94M
Market Cap 1.11B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Notable Two Hundred Day Moving Average Cross - RTRX

Notable Two Hundred Day Moving Average Cross - RTRX

In trading on Monday, shares of Retrophin, Inc. crossed below their 200 day moving average of $22.55, changing hands as low as $22.50 per share.

Retrophin Provides Corporate Update And 2018 Outlook

Retrophin Provides Corporate Update And 2018 Outlook

Preliminary full-year 2017 revenue of approximately $155 million

Retrophin Announces Presentation Of New Data From Physician-Initiated Treatment With Fosmetpantotenate At The Child Neurology Society's 26th Annual Meeting

Retrophin Announces Presentation Of New Data From Physician-Initiated Treatment With Fosmetpantotenate At The Child Neurology Society's 26th Annual Meeting

Patient with PKAN showed persistent improvement in function over 30-month period of treatment with fosmetpantotenate

Martin Shkreli Was Just Convicted on 3 Counts of Securities Fraud

Martin Shkreli Was Just Convicted on 3 Counts of Securities Fraud

"Pharma bro" Martin Shkreli was found guilty on three of eight counts of securities fraud.

Retrophin Commences Patient Dosing In International, Registrational Phase 3 Trial Of RE-024 In PKAN

Retrophin Commences Patient Dosing In International, Registrational Phase 3 Trial Of RE-024 In PKAN

FORT Study to assess efficacy and safety of novel replacement therapy

First Witness to Testify in Pharma Bro's Trial Felt 'Betrayed'

First Witness to Testify in Pharma Bro's Trial Felt 'Betrayed'

Sarah Hassan, daughter of pharmaceutical executive Fred Hassan, was ignored by Shkreli for nearly a year before she received returns on her original investment.

Juror Selection In Martin Shkreli Case Drags Into a Third Day

Juror Selection In Martin Shkreli Case Drags Into a Third Day

More than 250 jurors have been interviewed, but there's still no luck in assembling a jury for the so-called 'Pharma Bro.'

First Amendment Needs to 'Take a Backseat' in Pharma Bro Trial: Lawyer

First Amendment Needs to 'Take a Backseat' in Pharma Bro Trial: Lawyer

The 'Pharma Bro's' lawyer attempts to bar the press again from 'Pharma Bro's' hearing.

Commit To Purchase Retrophin At $12.50, Earn 10.4% Using Options

Commit To Purchase Retrophin At $12.50, Earn 10.4% Using Options

Investors eyeing a purchase of Retrophin, Inc. stock, but cautious about paying the going market price of $19.48/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Potential Jurors Lambaste 'Pharma Bro' Shkreli as Judge Calls 180 People to Fill Just 18 Spots

Potential Jurors Lambaste 'Pharma Bro' Shkreli as Judge Calls 180 People to Fill Just 18 Spots

One juror said Shkreli is 'the face of corporate greed in America.'

Pharma Bro's Trial to Begin Monday

Pharma Bro's Trial to Begin Monday

The trial for Martin Shkreli, the man alleged to have cheated investors and increasing a medication price by 5,000%, will begin today.

TheStreet Quant Rating: C- (Hold)